Back

CMS subsidiary wins China approval for Lumirix atopic dermatitis treatment

Verifying
  • Dermavon received NMPA approval for Lumirix® to treat mild to moderate atopic dermatitis.
  • Lumirix® achieved week-eight IGA responses of 63.0% versus 9.2% for placebo.
  • Lumirix® was first approved in China in January 2026 for vitiligo treatment.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.